Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapeutics for the treatment of Alzheimer's and other neurodegenerative diseases. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, which is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is based in Charlottesville, Virginia.
IPO Year: 2021
Exchange: NASDAQ
Website: acumenpharm.com
Date | Price Target | Rating | Analyst |
---|---|---|---|
7/26/2024 | $7.00 | Buy | Citigroup |
12/12/2023 | $8.00 | Buy | Deutsche Bank |
7/20/2023 | $9.00 → $14.00 | Buy | BofA Securities |
5/18/2023 | $13.00 | Overweight | Cantor Fitzgerald |
7/15/2022 | $15.00 | Buy | BTIG Research |
6/30/2022 | $15.00 | Buy | H.C. Wainwright |
1/21/2022 | $16.00 → $14.00 | Neutral → Buy | B of A Securities |
7/26/2021 | $27.00 | Buy | UBS |
7/26/2021 | $27.00 | Buy | Stifel |
7/26/2021 | $20.00 | Neutral | BofA Securities |
NEWTON, Mass., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, announced today that management will participate in a fireside chat at the H.C. Wainwright 26th Annual Global Investor Conference on Tuesday, Sept. 10, 2024, at 1:30 p.m. ET. The live webcast may be accessed under the Investors tab on www.acumenpharm.com and will be archived for 90 days. About Acumen Pharmaceuticals, Inc. Acumen Pharmaceuticals is a clinical-stage biopharmaceutical company developing a novel therapeutic that target
Actively enrolling subjects in ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer's disease Dosed the first subject in a Phase 1 study to support subcutaneous administration of sabirnetug in July 2024 with topline results anticipated in the first quarter of 2025 Cash, cash equivalents and marketable securities of $281.4 million as of Jun. 30, 2024, expected to support current clinical and operational activities into the first half of 2027 Company to host conference call and webcast today at 8:00 a.m. ET NEWTON, Mass., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) ("Acumen" or the "Company"), a clinical-sta
NEWTON, Mass., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) ("Acumen" or the "Company"), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, today announced that the Company will report second quarter 2024 financial results on Tuesday, August 13, 2024. The Company will host a conference call and live audio webcast at 8:00 a.m. ET to provide a business and financial update. To participate in the live conference call, please register using this link. After registration, you will be informed of the dial-in numbers including PIN. Please register a
NEWTON, Mass., July 29, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AβOs) in the brain for the treatment of Alzheimer's disease (AD), today announced that the first subject has been dosed with a subcutaneous formulation of sabirnetug (ACU193) in a Phase 1 pharmacokinetic (PK) comparison study. The study plans to compare the PK between subcutaneous and intravenous administrations of sabirnetug in healthy volunteers. Acumen's subcutaneous formulation of sabirnetug is co-formulated with Halozyme's proprietary ENHANZE® drug delivery technology (recomb
NEWTON, Mass., July 28, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease (AD), today announced new findings from its Phase 1 INTERCEPT-AD study of sabirnetug (ACU193). The research highlights the experiences of patients in the clinical trial to inform development of future trials, biomarker data to support sabirnetug's mechanism of action, and an ultra-sensitive method of measuring small amounts of sabirnetug in cerebrospinal fluid (CSF). The posters will be presented at the Alzheimer's Association In
NEWTON, Mass., July 11, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease (AD), today announced that the Company will present patient experience and biomarker data from its Phase 1 INTERCEPT-AD study of sabirnetug (ACU193) at the Alzheimer's Association International Conference (AAIC®) 2024 taking place in Philadelphia and online from July 28 – Aug. 1, 2024. The posters expand upon biomarker data associated with sabirnetug, methods for detecting levels of sabirnetug in cerebrospinal fluid (CSF), and pr
Announced initiation of ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer's disease, in May 2024Initiation of a Phase 1 study to support a subcutaneous dosing option of sabirnetug expected in mid-2024Cash, cash equivalents and marketable securities of $296.6 million as of Mar. 31, 2024, expected to support current clinical and operational activities into the first half of 2027Company to host conference call and webcast today at 8:00 a.m. ET CHARLOTTESVILLE, Va., May 14, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) ("Acumen" or the "Company"), a clinical-stage biopharmaceutical company developing a novel therapeuti
CHARLOTTESVILLE, Va., May 13, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, announced today that management will participate in a fireside chat at the H.C. Wainwright 2nd Annual BioConnect Conference on Monday, May 20, 2024, at 12:30 p.m. ET. The live webcast may be accessed under the Investors tab on www.acumenpharm.com and will be archived for 90 days. About Acumen Pharmaceuticals, Inc. Acumen, headquartered in Charlottesville, VA, with additional offices in Indianapolis, IN and Newton, MA, is
CHARLOTTESVILLE, Va., May 08, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, announced today that management will participate in a fireside chat at the 2024 Bank of America Healthcare Conference on Wednesday, May 15, 2024, at 8:55 a.m. PT (11:55 a.m. ET). The live webcast may be accessed under the Investors tab on www.acumenpharm.com and will be archived for 90 days. About Acumen Pharmaceuticals, Inc. Acumen, headquartered in Charlottesville, VA, with additional offices in Indianapolis, IN and Newton,
CHARLOTTESVILLE, Va., May 08, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease (AD), today announced that the first patient has been dosed with sabirnetug (ACU193) in the ALTITUDE-AD Phase 2 clinical trial designed to evaluate the clinical efficacy and safety of sabirnetug in patients with early AD. "Today marks a significant milestone for Acumen and the Alzheimer's community as we begin the Phase 2 trial of sabirnetug," said Daniel O'Connell, Chief Executive Officer of Acumen. "Sabirnetug is at the
4 - Acumen Pharmaceuticals, Inc. (0001576885) (Issuer)
4 - Acumen Pharmaceuticals, Inc. (0001576885) (Issuer)
4 - Acumen Pharmaceuticals, Inc. (0001576885) (Issuer)
4 - Acumen Pharmaceuticals, Inc. (0001576885) (Issuer)
4 - Acumen Pharmaceuticals, Inc. (0001576885) (Issuer)
4 - Acumen Pharmaceuticals, Inc. (0001576885) (Issuer)
4 - Acumen Pharmaceuticals, Inc. (0001576885) (Issuer)
4 - Acumen Pharmaceuticals, Inc. (0001576885) (Issuer)
3 - Acumen Pharmaceuticals, Inc. (0001576885) (Issuer)
4 - Acumen Pharmaceuticals, Inc. (0001576885) (Issuer)
CHARLOTTESVILLE, Va., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, announced today the appointment of James Doherty, Ph.D., as President and Chief Development Officer, effective February 1, 2024, reporting to Daniel O'Connell, Chief Executive Officer. Dr. Doherty's responsibilities will include oversight of clinical and non-clinical development, chemistry, manufacturing & controls and regulatory functions. "We are extremely excited to welcome Jim, who brings extensive experience and demonstrat
CHARLOTTESVILLE, Va. and CARMEL, Ind., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) ("Acumen" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of novel targeted therapeutics for Alzheimer's disease (AD), today announced Derrell Porter, M.D., has joined its Board of Directors. "We are thrilled to welcome Dr. Porter to our Board of Directors at a time when we're rapidly advancing clinical development of ACU193," said Daniel O'Connell, President and Chief Executive Officer of Acumen Pharmaceuticals. "Dr. Porter brings significant expertise in drug development and commercialization to the Board as we develop a novel and p
10-Q - Acumen Pharmaceuticals, Inc. (0001576885) (Filer)
8-K - Acumen Pharmaceuticals, Inc. (0001576885) (Filer)
8-K - Acumen Pharmaceuticals, Inc. (0001576885) (Filer)
10-Q - Acumen Pharmaceuticals, Inc. (0001576885) (Filer)
8-K - Acumen Pharmaceuticals, Inc. (0001576885) (Filer)
EFFECT - Acumen Pharmaceuticals, Inc. (0001576885) (Filer)
ARS - Acumen Pharmaceuticals, Inc. (0001576885) (Filer)
DEFA14A - Acumen Pharmaceuticals, Inc. (0001576885) (Filer)
DEF 14A - Acumen Pharmaceuticals, Inc. (0001576885) (Filer)
S-3 - Acumen Pharmaceuticals, Inc. (0001576885) (Filer)
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease (AD), today announced that the Company will present patient experience and biomarker data from its Phase 1 INTERCEPT-AD study of sabirnetug (ACU193) at the Alzheimer's Association International Conference (AAIC®) 2024 taking place in Philadelphia and online from July 28 – Aug. 1, 2024. The posters expand upon biomarker data associated with sabirnetug, methods for detecting levels of sabirnetug in cerebrospinal fluid (CSF), and provide insights on patients' experiences in the INTE
HC Wainwright & Co. analyst Andrew Fein reiterates Acumen Pharmaceuticals (NASDAQ:ABOS) with a Buy and maintains $15 price target.
Gainers CareCloud (NASDAQ:CCLDO) stock moved upwards by 46.1% to $15.5 during Tuesday's pre-market session. Syra Health (NASDAQ:SYRA) shares increased by 33.08% to $1.77. The market value of their outstanding shares is at $11.6 million. As per the press release, Q1 earnings came out 3 days ago. Vaxart (NASDAQ:VXRT) shares moved upwards by 20.71% to $0.99. The company's market cap stands at $175.0 million. As per the news, the Q1 earnings report came out yesterday. Sharps Technology (NASDAQ:STSS) shares rose 15.72% to $0.26. The company's market cap stands at $4.0 million. Harrow (NASDAQ:HROW) shares rose 12.84% to $13.62. The company's market cap stands at $481.8 million. As per the new
Acumen Pharmaceuticals (NASDAQ:ABOS) reported quarterly losses of $(0.25) per share which beat the analyst consensus estimate of $(0.27) by 7.41 percent. This is a 10.71 percent increase over losses of $(0.28) per share from the same period last year.
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease (AD), today announced that the first patient has been dosed with sabirnetug (ACU193) in the ALTITUDE-AD Phase 2 clinical trial designed to evaluate the clinical efficacy and safety of sabirnetug in patients with early AD. "Today marks a significant milestone for Acumen and the Alzheimer's community as we begin the Phase 2 trial of sabirnetug," said Daniel O'Connell, Chief Executive Officer of Acumen. "Sabirnetug is at the forefront of the next generation of Alzheimer's therapies,
https://blog.tipranks.com/these-2-strong-buy-penny-stocks-are-poised-for-over-300-gains-say-analysts/
Presentation and poster include deeper data insights on sabirnetug safety profile, target engagement and fluid biomarker changesPresentation to be featured during AAN Emerging Science SessionCompany on track to initiate Phase 2 trial evaluating sabirnetug in first half of 2024 CHARLOTTESVILLE, Va., April 16, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease (AD), will present the comprehensive clinical and biomarker results from its positive Phase 1 INTERCEPT-AD study of sabirnetug (ACU193) in early AD d
HC Wainwright & Co. analyst Andrew Fein maintains Acumen Pharmaceuticals (NASDAQ:ABOS) with a Buy and maintains $15 price target.
SC 13G/A - Acumen Pharmaceuticals, Inc. (0001576885) (Subject)
SC 13G - Acumen Pharmaceuticals, Inc. (0001576885) (Subject)
SC 13G/A - Acumen Pharmaceuticals, Inc. (0001576885) (Subject)
SC 13D/A - Acumen Pharmaceuticals, Inc. (0001576885) (Subject)
SC 13G/A - Acumen Pharmaceuticals, Inc. (0001576885) (Subject)
SC 13G/A - Acumen Pharmaceuticals, Inc. (0001576885) (Subject)
SC 13G/A - Acumen Pharmaceuticals, Inc. (0001576885) (Subject)
SC 13G/A - Acumen Pharmaceuticals, Inc. (0001576885) (Subject)
SC 13G - Acumen Pharmaceuticals, Inc. (0001576885) (Subject)
SC 13G - Acumen Pharmaceuticals, Inc. (0001576885) (Subject)
Actively enrolling subjects in ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer's disease Dosed the first subject in a Phase 1 study to support subcutaneous administration of sabirnetug in July 2024 with topline results anticipated in the first quarter of 2025 Cash, cash equivalents and marketable securities of $281.4 million as of Jun. 30, 2024, expected to support current clinical and operational activities into the first half of 2027 Company to host conference call and webcast today at 8:00 a.m. ET NEWTON, Mass., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) ("Acumen" or the "Company"), a clinical-sta
NEWTON, Mass., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) ("Acumen" or the "Company"), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, today announced that the Company will report second quarter 2024 financial results on Tuesday, August 13, 2024. The Company will host a conference call and live audio webcast at 8:00 a.m. ET to provide a business and financial update. To participate in the live conference call, please register using this link. After registration, you will be informed of the dial-in numbers including PIN. Please register a
Announced initiation of ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer's disease, in May 2024Initiation of a Phase 1 study to support a subcutaneous dosing option of sabirnetug expected in mid-2024Cash, cash equivalents and marketable securities of $296.6 million as of Mar. 31, 2024, expected to support current clinical and operational activities into the first half of 2027Company to host conference call and webcast today at 8:00 a.m. ET CHARLOTTESVILLE, Va., May 14, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) ("Acumen" or the "Company"), a clinical-stage biopharmaceutical company developing a novel therapeuti
CHARLOTTESVILLE, Va., May 07, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) ("Acumen" or the "Company"), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, today announced that the Company will report first quarter 2024 financial results on Tuesday, May 14, 2024. The Company will host a conference call and live audio webcast at 8:00 a.m. ET to provide a business and financial update. To participate in the live conference call, please register using this link. After registration, you will be informed of the dial-in numbers including PIN. Please register a
CHARLOTTESVILLE, Va., March 19, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) ("Acumen" or the "Company"), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, today announced that the Company will report fourth quarter and year-end 2023 financial results on Tuesday, March 26, 2024. The Company will host a conference call and live audio webcast at 8:00 a.m. ET to provide a business and financial update. To participate in the live conference call, please register using this link. After registration, you will be informed of the dial-in numbers including PIN.
CHARLOTTESVILLE, VA. and INDIANAPOLIS, IN., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) ("Acumen" or the "Company"), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, today announced that the Company will report third quarter financial results on Monday, Nov. 13, 2023. The Company will host a conference call and live audio webcast at 8:00 a.m. ET to provide a business and financial update. To participate in the live conference call, please register using this link. After registration, you will be informed of the dial-in numbers including PIN.
CHARLOTTESVILLE, Va. and CARMEL, Ind., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) ("Acumen" or the "Company"), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease, today announced that the Company will report second quarter financial results on Tuesday, August 8, 2023. The Company will host a conference call and live audio webcast at 8:00 a.m. ET to provide a business and financial update. To participate in the live conference call, please register using this link. After registration, you will be informed of the dial-in numbers including
CHARLOTTESVILLE, Va. and CARMEL, Ind., July 17, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease (AD), will hold a conference call today to discuss the positive topline results from the Phase 1 INTERCEPT-AD trial of ACU193, the first clinical-stage AβO targeting antibody therapy in early AD. To read more about the results, please see the press release here. Conference Call Details Acumen will host a webcast presentation and conference call for analysts and investors today, July 17, 2023, at 8:00 a.m. ET t
Topline results from INTERCEPT-AD trial met primary and secondary objectives, demonstrating proof-of-mechanism for ACU193, the first clinical-stage amyloid beta oligomer (AβO)-targeting antibody Rapid, dose-related, statistically significant (p=0.01) amyloid plaque reduction observed within higher dose cohorts (25% reduction in 60 mg/kg Q4W cohort at day 63 and 20% reduction in 25 mg/kg Q2W cohort at day 70) ACU193 approached maximal central target engagement of toxic AβOs beyond expected levels, establishing broad therapeutic index and path to convenient monthly dosing ACU193 was well-tolerated in patients with early Alzheimer's disease and resulted in no drug-related serious adverse even
Topline results for ACU193, the first clinical stage amyloid beta oligomer (AβO)-directed antibody, to provide deeper insight into candidate's therapeutic potential for the treatment of early Alzheimer's diseasePhase 1 INTERCEPT-AD data investigating safety, pharmacokinetics and target engagement of ACU193 to be included in a Featured Research Session as a Developing Topics oral presentation on July 16Company to host conference call and webcast for investors and analysts July 17 at 8 a.m. ET CHARLOTTESVILLE, Va. and CARMEL, Ind., June 13, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that tar
Citigroup initiated coverage of Acumen Pharmaceuticals with a rating of Buy and set a new price target of $7.00
Deutsche Bank initiated coverage of Acumen Pharmaceuticals with a rating of Buy and set a new price target of $8.00
BofA Securities resumed coverage of Acumen Pharmaceuticals with a rating of Buy and set a new price target of $14.00 from $9.00 previously
Cantor Fitzgerald initiated coverage of Acumen Pharmaceuticals with a rating of Overweight and set a new price target of $13.00
BTIG Research initiated coverage of Acumen Pharmaceuticals with a rating of Buy and set a new price target of $15.00
H.C. Wainwright initiated coverage of Acumen Pharmaceuticals with a rating of Buy and set a new price target of $15.00
B of A Securities upgraded Acumen Pharmaceuticals from Neutral to Buy and set a new price target of $14.00 from $16.00 previously
UBS initiated coverage of Acumen Pharmaceuticals with a rating of Buy and set a new price target of $27.00
Stifel initiated coverage of Acumen Pharmaceuticals with a rating of Buy and set a new price target of $27.00
BofA Securities initiated coverage of Acumen Pharmaceuticals with a rating of Neutral and set a new price target of $20.00